Tonix Pharmaceuticals Holdings CEO Dr Seth Lederman joined Steve Darling from Proactive to announced that the first patient has been dosed in the Phase 2 OASIS trial, a study evaluating TNX-102 SL for reducing the severity of acute stress reaction (ASR) and preventing the onset of acute stress disorder (ASD). The investigator-initiated trial is sponsored by the University of North Carolina Institute for Trauma Recovery and supported by a $3 million grant from the U.S. Department of Defense. The OASIS (Optimizing Acute Stress Reaction Interventions with TNX-102 SL) trial will assess the safety and efficacy of TNX-102 SL 5.6 mg compared to placebo in reducing post-traumatic neuropsychiatric outcomes in patients treated in the emergency department (ED) after motor vehicle collisions (MVCs). Approximately 180 patients will be enrolled and randomized across U.S. ED study sites. This trial builds on infrastructure and insights from UNC’s $40 million AURORA initiative, a large-scale national research program aimed at improving outcomes for individuals affected by traumatic events. AURORA is backed by the NIH, One Mind, private foundations, and tech companies including Mindstrong Health and Verily Life Sciences, a subsidiary of Alphabet (Google’s parent company). Tonix aims to address the significant unmet need for early treatment of ASR in both civilian and military trauma populations. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #MPOXVaccine #Smallpox #TNX801 #VaccineDevelopment #ClinicalTrials #PharmaceuticalNews #MedicalResearch #WHO #GlobalHealth #InfectiousDiseases #Biopharma #ProactiveInvestors